Ipsen

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience, and Rare Diseases. Ipsen also has a well-established Consumer Healthcare business. With a direct commercial presence in over 30 countries, Ipsen's global reach is further extended through its network of trusted partners in countries where it does not have a direct presence.

History

The origins of Ipsen can be traced back to 1929, when Henri Beaufour founded the company in France. Over the decades, Ipsen has grown from a modest French pharmaceutical company into a global biopharmaceutical leader. The company's growth has been driven by significant research and development efforts, strategic acquisitions, and a focus on developing innovative therapies for diseases with high unmet medical needs.

Therapeutic Areas

Oncology

In the field of Oncology, Ipsen focuses on developing treatments for various types of cancer. The company's oncology portfolio includes innovative therapies for thyroid cancer, neuroendocrine tumors, and renal cell carcinoma, among others.

Neuroscience

Ipsen's Neuroscience portfolio is dedicated to addressing complex conditions such as spasticity, cervical dystonia, and hemifacial spasm. The company's commitment to neuroscience is underscored by its development of treatments that improve the quality of life for patients suffering from these debilitating conditions.

Rare Diseases

The Rare Diseases therapeutic area is a key focus for Ipsen, with efforts aimed at addressing unmet medical needs in diseases that are often overlooked. Ipsen's rare disease portfolio includes treatments for conditions such as acromegaly and fibrodysplasia ossificans progressiva.

Research and Development

Ipsen's commitment to innovation is evident in its robust research and development (R&D) pipeline. The company invests significantly in R&D to discover and develop new therapies that can offer better outcomes for patients. Ipsen's R&D strategy is focused on leveraging cutting-edge science and technologies, including peptide technology and targeted radiopharmaceuticals, to develop next-generation treatments.

Corporate Responsibility

Ipsen is committed to acting responsibly and ethically in all aspects of its business. The company's corporate responsibility strategy focuses on three key areas: patient care, environmental sustainability, and social responsibility. Ipsen aims to make a positive impact on society and the environment while ensuring the highest standards of ethical conduct.

Global Presence

With its headquarters in Paris, France, Ipsen operates globally, with a direct commercial presence in more than 30 countries and products available in over 115 countries. The company's global footprint allows it to deliver innovative medicines to patients worldwide.

Conclusion

Ipsen stands out in the biopharmaceutical industry for its focus on specialty care and commitment to addressing unmet medical needs in Oncology, Neuroscience, and Rare Diseases. Through its innovative R&D efforts, global presence, and dedication to corporate responsibility, Ipsen continues to make a significant impact on patients' lives around the world.